Payday Redux: Deals, Deals, and more Deals
It's been difficult to keep up with all the deals this month! We won't review them all here, as that's best done by others. But here are a…
Menu
Drug Delivery is Alive and Well
The announcement of the Allergan acquisition of MAP Pharmaceuticals for nearly $1 billion (and the NuPathe approval) is a good reminder of the potential value (both clinical and financial) of reformulation and drug…
Predictions for 2013
Happy New Year! For many companies, 2012 was a challenging year. How will 2013 play out? Here are a few ideas we've discussed internally as we look forward to 2013:…
Abandon R&D for M&A? Vote today!
In response to the recent acquisition of Medicis by Valeant, an interesting poll underway asking a seemingly simple question, "Will other pharma companies follow Valeant and abandon R&D in favor…
Looking for a job in pharma? Good luck
Today, KPMG is reporting results from a survey of pharmaceutical executives. In this survey, respondents said they will increase their acquisition activity in the coming year in order to gain…